Literature DB >> 32146081

Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab.

Satya Das1, Audrey Allen2, Jordan Berlin2.   

Abstract

Entities:  

Keywords:  Anti-cytotoxic T-lymphocyte-associated protein 4; Anti-programmed cell death protein 1; Checkpoint inhibitor progression; Metastatic colon cancer; Mismatch repair deficiency

Mesh：

Substances：

Year:  2020        PMID： 32146081      PMCID： PMC7261248          DOI： 10.1016/j.clcc.2020.02.006

Source DB:  PubMed          Journal:  Clin Colorectal Cancer        ISSN： 1533-0028            Impact factor:   4.481


× No keyword cloud information.
  12 in total

1.  Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

Authors:  Michael J Overman; Ray McDermott; Joseph L Leach; Sara Lonardi; Heinz-Josef Lenz; Michael A Morse; Jayesh Desai; Andrew Hill; Michael Axelson; Rebecca A Moss; Monica V Goldberg; Z Alexander Cao; Jean-Marie Ledeine; Gregory A Maglinte; Scott Kopetz; Thierry André
Journal:  Lancet Oncol       Date:  2017-07-19       Impact factor: 41.316

Review 2.  Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.

Authors:  Spencer C Wei; Colm R Duffy; James P Allison
Journal:  Cancer Discov       Date:  2018-08-16       Impact factor: 39.397

Review 3.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

4.  Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.

Authors:  Lisa Zimmer; Susmitha Apuri; Zeynep Eroglu; Lisa A Kottschade; Andrea Forschner; Ralf Gutzmer; Max Schlaak; Lucie Heinzerling; Angela M Krackhardt; Carmen Loquai; Svetomir N Markovic; Richard W Joseph; Kelly Markey; Jochen S Utikal; Carsten Weishaupt; Simone M Goldinger; Vernon K Sondak; Jonathan S Zager; Dirk Schadendorf; Nikhil I Khushalani
Journal:  Eur J Cancer       Date:  2017-02-17       Impact factor: 9.162

Review 5.  Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.

Authors:  Tuba N Gide; James S Wilmott; Richard A Scolyer; Georgina V Long
Journal:  Clin Cancer Res       Date:  2017-11-10       Impact factor: 12.531

6.  Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.

Authors:  A B Schrock; C Ouyang; J Sandhu; E Sokol; D Jin; J S Ross; V A Miller; D Lim; I Amanam; J Chao; D Catenacci; M Cho; F Braiteh; S J Klempner; S M Ali; M Fakih
Journal:  Ann Oncol       Date:  2019-07-01       Impact factor: 32.976

7.  Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

Authors:  Michael J Overman; Sara Lonardi; Ka Yeung Mark Wong; Heinz-Josef Lenz; Fabio Gelsomino; Massimo Aglietta; Michael A Morse; Eric Van Cutsem; Ray McDermott; Andrew Hill; Michael B Sawyer; Alain Hendlisz; Bart Neyns; Magali Svrcek; Rebecca A Moss; Jean-Marie Ledeine; Z Alexander Cao; Shital Kamble; Scott Kopetz; Thierry André
Journal:  J Clin Oncol       Date:  2018-01-20       Impact factor: 44.544

8.  CTLA4 blockade broadens the peripheral T-cell receptor repertoire.

Authors:  Lidia Robert; Jennifer Tsoi; Xiaoyan Wang; Ryan Emerson; Blanca Homet; Thinle Chodon; Stephen Mok; Rong Rong Huang; Alistair J Cochran; Begoña Comin-Anduix; Richard C Koya; Thomas G Graeber; Harlan Robins; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

Review 9.  Mechanisms of resistance to immune checkpoint inhibitors.

Authors:  Russell W Jenkins; David A Barbie; Keith T Flaherty
Journal:  Br J Cancer       Date:  2018-01-02       Impact factor: 7.640

Review 10.  CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.

Authors:  Elizabeth I Buchbinder; Anupam Desai
Journal:  Am J Clin Oncol       Date:  2016-02       Impact factor: 2.339
View more
  6 in total

1.  Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy.

Authors:  Marc T Roth; Satya Das
Journal:  Expert Rev Anticancer Ther       Date:  2020-12-04       Impact factor: 4.512

2.  SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis.

Authors:  Kevin Tong; Om A Kothari; Katherine S Haro; Anshuman Panda; Manisha M Bandari; Jillian N Carrick; Joseph J Hur; Lanjing Zhang; Chang S Chan; Jinchuan Xing; Michael L Gatza; Shridar Ganesan; Michael P Verzi
Journal:  Oncogene       Date:  2021-08-27       Impact factor: 9.867

3.  Durable Responses in Patients With Advanced Cholangiocarcinoma on Sequential Dual-agent Immunotherapy After Progressing on Single-agent Immunotherapy.

Authors:  Dalia Kaakour; Garo Hagopian; Sonia Lee; Fa Chyi Lee
Journal:  Am J Clin Oncol       Date:  2022-09-14       Impact factor: 2.787

Review 4.  Liver Immune Microenvironment and Metastasis from Colorectal Cancer-Pathogenesis and Therapeutic Perspectives.

Authors:  Xuezhen Zeng; Simon E Ward; Jingying Zhou; Alfred S L Cheng
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

5.  High Expression of Pd-1 in Circulating Cells of Patients With Advanced Colorectal Cancer Receiving Adjuvant Therapy.

Authors:  Muhammed A Bakhrebah; Mohammad Nasrullah; Wesam H Abdulaal; Mohammed A Hassan; Halima Siddiqui; Huda Al Doghaither; Ulfat M Omar; Nawal Helmi; Mohannad M Fallatah; Ayat B Al-Ghafari; Mohammad Imran Khan; Hani Choudhry
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

6.  Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer.

Authors:  Pashtoon Murtaza Kasi; Griffin Budde; Michael Krainock; Vasily N Aushev; Allyson Koyen Malashevich; Meenakshi Malhotra; Perry Olshan; Paul R Billings; Alexey Aleshin
Journal:  J Immunother Cancer       Date:  2022-01       Impact factor: 13.751
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.